Search Results - Peter Foley

Pityriasis rosea-like drug eruption secondary to deucravacitinib by Nisal Punchihewa, MD, Senhong Lee, MBBS, Chin-Guan Tan, MBBS, Peter Foley, MD

Connect to this object online.

Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis by April W. Armstrong, Peter Foley, Yan Liu, Megan Miller, Rachel E. Teneralli, Anthony Bewley, Kenneth B. Gordon, Kim A. Papp, Chenglong Han

Connect to this object online.

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis by Jonathan I. Silverberg, Eric L. Simpson, Mark Boguniewicz, Marjolein S. De Bruin-Weller, Peter Foley, Yoko Kataoka, Gaëlle Bégo-, Zhen Chen, Brad Shumel, Jingdong Chao, Ana B. Rossi

Connect to this object online.

Efficacy and safety analysis: 24‐month outcomes from a prospective cohort of 106 fields treated with widefield radiation therapy for extensive skin field cancerization, with or wit... by Lynda Spelman, Andrew E. Potter, Chris Baker, Stephen Shumack, Robert Sinclair, David Christie, Bradley Wong, Peter Foley, Steven Hacker, Cody C. Allison, the National Dermatology Radiation Oncology Registry (NDROR)

Connect to this object online.

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies by Marjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, Mette Deleuran, Peter Foley, Giampiero Girolomoni, Jana Hercogová, Chih-Ho Hong, Norito Katoh, Andrew E. Pink, Marie-Aleth Richard, Stephen Shumack, Juan F. Silvestre, Stephan Weidinger

Connect to this object online.

The Treat-to-Target Project in Atopic Dermatitis: One Year On by Marjolein de Bruin-Weller, Mette Deleuran, Tilo Biedermann, Robert Bissonnette, Peter Foley, Giampiero Girolomoni, Jana Hercogová, Chih-Ho Hong, Norito Katoh, Andrew Pink, Marie-Aleth Richard, Stephen Shumack, Juan Francisco Silvestre, Jacob P. Thyssen, Stephan Weidinger

Connect to this object online.

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials by Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt

Connect to this object online.

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials by Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher E. M. Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin, Kim Papp

Connect to this object online.